ACE inhibitors or ARBs are also suggested for patients with stage 1 or stage 2 CKD with significant albuminuria, which is defined as -≥300 mg/d or ≥300 mg/g of albumin-creatinine ratio or equivalent in the first void in the morning. This evidence concerns the gene ACE and chronic kidney disease.